Business Wire

Holicity Board Urges Stockholders to Vote TODAY in Support of Business Combination with Astra Space, Inc.

29.6.2021 18:56:00 EEST | Business Wire | Press release

Share

Holicity Inc. (“Holicity” or the “Company”) (NASDAQ: HOL) issued the following statement to Holicity stockholders reiterating the Holicity Board of Directors’ recommendation in favor of the transaction with Astra Space, Inc. (“Astra”), pursuant to the Business Combination Agreement, dated February 2, 2021, by and between Astra, Holicity and Holicity Merger Sub Inc, a wholly-owned subsidiary of Holicity (the “Business Combination Agreement”).

Holicity Inc. is scheduled to hold a Special Meeting of Stockholders at 8:00 AM ET on June 30, 2021 to approve a business combination with Astra Space, Inc. We are asking stockholders that held shares of Holicity Inc. on May 24, 2021 (the record date) to cast their vote so that their shares are represented at the June 30 meeting. Your vote is extremely important; the closing of the business combination cannot happen without your support. The deadline for voting online is today , June 29th at 11:59 pm ET.

Stockholder interest has been strong, however if not enough shares are voted by the deadline, then the Special Meeting could fail to reach a quorum and cause the business combination to be delayed. A larger percentage of retail investors poses a unique challenge for us to reach stockholders who may not be accustomed to the process of voting in special meetings. “Retail investors may not always realize the importance that voting even a small number of shares can have in successfully completing a merger like this,” said Randy Russell, Chief Investment Officer of Holicity. “We believe this transaction is in the best interest of our stockholders, and it is critical that everyone who has the opportunity to vote do so."

If any stockholder wishes to take part in this process, they should contact their brokers to learn how to cast their vote, or visit www.holicity.inc.

Any stockholder can also contact Morrow Sodali LLC, Holicity’s proxy solicitor, by telephone at (800) 662-5200 or by email at HOL.info@investor.morrowsodali.com for help with voting or if they have any questions.

We thank you for your continued support of Holicity.

Important Information About the Business Combination and Where to Find It

In connection with the proposed Business Combination, the Company publicly filed with the SEC a registration statement on Form S-4 (the “Registration Statement”) on May 3, 2021 (Registration No. 333- 255703), which includes a proxy statement/prospectus, and certain other related documents, which will be both the proxy statement to be distributed to holders of shares of the Company’s common stock in connection with the Company’s solicitation of proxies for the vote by the Company’s stockholders with respect to the Business Combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities of the Company to be issued in the Business Combination. The registration statement became effective on June 4, 2021. The Company’s stockholders and other interested persons are advised to read the proxy statement/prospectus included in the Registration Statement and the amendments thereto, as these materials will contain important information about the parties to the Business Combination Agreement, the Company and the Business Combination. The definitive proxy statement/prospectus was mailed on or about June 7, 2021 to stockholders of the Company as of a record date established for voting on the Business Combination and other matters as may be described in the Registration Statement. Stockholders are able to obtain copies of the proxy statement/prospectus and other documents filed with the SEC that will be incorporated by reference in the proxy statement/prospectus, without charge, at the SEC’s web site at sec.report, or by directing a request to: Holicity Inc., 2300 Carillon Point, Kirkland, WA 98033, Attention: Craig McCaw, Chief Executive Officer, (425) 278-7100.

Participants in the Solicitation

The Company and its directors and executive officers may be deemed participants in the solicitation of proxies from the Company’s stockholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in the Company is contained in the Company’s registration statement on Form S-1, which was initially filed with the SEC on July 17, 2020, and is available free of charge at the SEC’s web site at sec.gov, or by directing a request to Holicity Inc., 2300 Carillon Point, Kirkland, WA 98033, Attention: Secretary, (425) 278-7100. Additional information regarding the interests of such participants is contained in the Registration Statement.

Astra and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the Business Combination is contained in the Registration Statement.

Forward-Looking Statements

This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company’s and Astra’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s and Astra’s expectations with respect to future performance and anticipated financial impacts of the Business Combination and the Mergers, the satisfaction of the closing conditions to the Business Combination and the Mergers and the timing of the completion of the Business Combination and the Mergers. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside the Company’s and Astra’s control and are difficult to predict. The Company and Astra caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company and Astra do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Astra

Media
kati@astra.com

Investors
investors@astra.com

Carolyn Bass
Market Street Partners
cbass@marketstreetpartners.com

Holicity

Media
Todd Wolfenbarger
todd@summitslc.com
+1(801) 244-9600

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Clinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive Chairperson13.8.2026 17:05:00 EEST | Press release

Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced leadership expansion. Laura Shannon joins the organization as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson. This expansion of the senior leadership team is a recognition of a growing organization with global capabilities and continuing commitment to advancing treatments for patients with psychiatric and neurological disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813362140/en/ Laura Shannon joins Clinilabs as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson Ms. Shannon is a dynamic leader with more than 30 years of biopharma industry experience, known for her ability to build high-performing teams, forge strategic alliances, and drive

Resurgens Technology Partners Invests in Qarma to Advance the Future of Quality and Compliance13.8.2026 16:00:00 EEST | Press release

Resurgens Technology Partners (“Resurgens”), a software-focused private equity firm, today announced its partnership with Qarma, a leading global provider of AI-powered quality and compliance software for brands, retailers, and manufacturers managing complex, global supply chains. Qarma has built a platform that combines best-practice quality and compliance with hands-on execution where it matters most, on the factory floor. Qarma will continue to be led by its Co-founders, CEO Jacob Nedergaard and CTO Søren Mønsted. Founded in 2016, Qarma serves customers across industries, including furniture and home, apparel, consumer goods, and electronics. Its platform connects quality and compliance teams, sourcing professionals, suppliers, and inspectors. Over the past decade, Qarma has built one of the industry’s deepest operational quality platforms, combining best-practice workflows with software designed to work natively on factory floors worldwide. This unique operational foundation has ge

Tecnotree allekirjoitti 17,5 miljoonan Yhdysvaltain dollarin monivuotisen sopimuksen nykyisen teleoperaattoriasiakkaan kanssa Amerikan alueella13.8.2026 15:04:00 EEST | Tiedote

Tecnotree, joka on maailmanlaajuinen 5G- ja tekoälynatiivien digitaalisten BSS-ratkaisujen sekä teleoperaattoreille suunnattujen digitaalisen transformaation ratkaisujen toimittaja, ilmoitti eilen allekirjoittaneensa uuden monivuotisen ja usean alueen kattavan sopimuksen nykyisen teleoperaattoriasiakkaan kanssa Amerikan alueella. Sopimus kuvastaa Tecnotreen jatkuvaa painotusta pitkäaikaisten asiakassuhteiden laajentamiseen yhtiön 5G- ja tekoälynatiivien digitaalisten alustojen ja palvelujen avulla, jotka auttavat teleoperaattoreita uudistamaan liiketoimintaansa, nopeuttamaan palveluinnovaatioita ja parantamaan asiakaskokemusta. Tecnotree jatkaa operaattoreiden muuttuvien digitaalisen transformaation painopisteiden tukemista maailmanlaajuisesti. ”Amerikan alue on Tecnotreelle edelleen tärkeä markkina-alue, jolla yhtiö jatkaa teleoperaattoreiden tukemista ratkaisuilla, jotka yksinkertaistavat toimintaa, mahdollistavat liiketoiminnan ketteryyden ja luovat kestävää arvoa seuraavan sukupolv

Vantage Data Centers and Nebius Expand UK AI Infrastructure with First Deployment in South Wales AI Growth Zone13.8.2026 15:00:00 EEST | Press release

Vantage Data Centers, a leading global provider of hyperscale data center campuses, and Nebius (Nasdaq: NBIS), the AI cloud company, today announced an agreement to deploy high-density, NVIDIA-powered AI infrastructure at Vantage’s CWL1 campus in Newport, Wales. The deployment represents the first announced commercial capacity commitment in the South Wales AI Growth Zone and will support growing UK demand for domestic AI compute capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813253918/en/ CWL13 data center at Vantage’s Newport, Wales, campus. Under the agreement, Nebius will lease high-density capacity at CWL1 to support AI training, inference, agentic AI and enterprise AI workloads, serving enterprises, researchers, startups and public sector organizations seeking access to advanced AI infrastructure. This capacity is part of Nebius’ broader UK expansion and commitment to scale domestic AI compute capacity. In

SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results13.8.2026 13:30:00 EEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the second quarter of fiscal year 2026 (the three months ended June 30, 2026) and the first half of fiscal year 2026 (the six months ended June 30, 2026). Second Quarter 2026 Financial Highlights Total revenues were $49 million, an increase of 13% year-over-year. Net income attributable to SBC Medical was $11 million, an increase of 335% year-over-year. Net income margin was 22%, an increase of 16 percentage points year-over-year. Adjusted EBITDA1 was $20 million, an increase of 32% year-over-year. Adjusted EBITDA margin1 was 41%, an increase of 6 percentage points year-over-year. Basic EPS was $0.10 for the three months ended June 30, 2026, an increase of 400% year-over-year. The Company believ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye